scholarly journals Twenty-four-month real-world visual outcomes of intravitreal aflibercept as monotherapy for the treatment of neovascular age-related macular degeneration

2019 ◽  
Vol 12 (2) ◽  
pp. 99
Author(s):  
Thomas Siempis ◽  
Mariam El Abiary ◽  
Radhika Patel ◽  
Manish Gupta
Keyword(s):  
Macular Degeneration ◽  
Real World ◽  
Age Related Macular Degeneration ◽  
Visual Outcomes ◽  
Age Related ◽  
Intravitreal Aflibercept

Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept at fixed intervals as per UK licence

2017 ◽  
Vol 46 (4) ◽  
pp. 407-411 ◽  
Author(s):  
Mehmet Ozturk ◽  
Martin L Harris ◽  
Vuong Nguyen ◽  
Daniel Barthelmes ◽  
Mark C Gillies ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Real World ◽  
Age Related Macular Degeneration ◽  
Visual Outcomes ◽  
Age Related

scholarly journals Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence

2020 ◽  
pp. bjophthalmol-2020-317434
Author(s):  
Vincent Daien ◽  
Robert P Finger ◽  
James S Talks ◽  
Paul Mitchell ◽  
Tien Y Wong ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Real World ◽  
Treatment Strategies ◽  
Age Related Macular Degeneration ◽  
Fixed Dose ◽  
Treatment Burden ◽  
Visual Outcomes ◽  
Anti Vegf ◽  
Age Related ◽  
Real World Evidence

The aim of this work was to evaluate the contribution of real-world evidence (RWE) in changing anti-vascular endothelial growth factor (VEGF) therapy treatment practices and improving real-world treatment strategies for neovascular age-related macular degeneration (nAMD).A PubMed literature search was performed to review the large number of English-language studies conducted to investigate the real-world effectiveness of anti-VEGF (aflibercept and ranibizumab) treatment paradigms available for nAMD.The evidence for pro re nata (PRN), treat-and-extend (T&E) and fixed bimonthly dosing regimens for anti-VEGF treatment of nAMD were reviewed and findings are summarised. RWE demonstrated that T&E regimens optimise visual outcomes while reducing burden on patients, clinics and physicians, compared with both fixed-dose and PRN regimens.RWE has helped to develop and improve real-world treatment strategies in nAMD, with the aim of optimising visual outcomes and reducing treatment burden in clinical practice. Of the various regimens, a T&E regimen is most likely to adequately balance clinical outcomes and treatment burden for patients with nAMD.

Sign in / Sign up

Export Citation Format

Share Document